Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI

The use of interleukin (IL)-15 or the IL-15 superagonist RLI as immunological adjuvants presents many advantages over that of IL-2, including a reduced toxicity and an improved efficacy. We have generated an immunocytokine that specifically targets RLI to a tumor-associated antigen, namely, disialog...

Descripción completa

Detalles Bibliográficos
Autores principales: Vincent, Marie, Quéméner, Agnès, Jacques, Yannick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3857326/
https://www.ncbi.nlm.nih.gov/pubmed/24349876
http://dx.doi.org/10.4161/onci.26441
Descripción
Sumario:The use of interleukin (IL)-15 or the IL-15 superagonist RLI as immunological adjuvants presents many advantages over that of IL-2, including a reduced toxicity and an improved efficacy. We have generated an immunocytokine that specifically targets RLI to a tumor-associated antigen, namely, disialoganglioside GD2. This agent displayed robust antitumor activity in 2 syngeneic murine models of malignant disease.

Ejemplares similares